Clayton Dehn currently serves as Chief Scientific Officer and Therapeutic Area Lead for Metabolism & Endocrinology at Evolution Research Group since 2021. Simultaneously, Clayton is a member of the Metabolic Disorders Steering Committee and the NIMBLE Leadership Team at the Foundation for the National Institutes of Health, contributing to advancements in non-invasive biomarkers for managing liver diseases. Previous roles include Vice President of Clinical Pharmacology Services at High Point Clinical Trials Center, Senior Vice President at Clinical Trials of Texas, Co-Founder and CEO of Umbrella Corporation, and Executive Director at Celerion. Clayton began academic pursuits at the University of Jamestown, working towards a PhD in Clinical Research, following a Master’s degree in Physiology from Texas Tech University.
This person is not in any teams
This person is not in any offices